Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04932031 · ClinicalTrials.gov registry record
Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy
A clinical trial, sponsored by Sapere Bio.
- Terminated
- Registry status
- 123
- Enrollment target
NCT04932031 is a clinical trial that was terminated before completion, run by Sapere Bio. The registered enrollment target is 123 participants.
The verdict
NCT04932031 was terminated before completion, sponsored by Sapere Bio.
- TERMINATED
- Registry status
- 123 participants
- Enrollment target
Study Summary
This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and the University of Alabama at Birmingham (UAB) Hospital). The primary purpose of this study to explore patient- and procedure-based variables that identify patients at risk for developing CIPN during chemotherapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2022-05-25 |
| Est. Completion | 2023-11-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04932031
The ClinicalTrials.gov registry entry for NCT04932031 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sapere Bio, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04932031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04932031 about?
NCT04932031 is a clinical study titled "Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy". This is an observational study to discover risk factors of chemotherapy-induced peripheral neuropathy (CIPN) in 350 patients with early stage breast cancer undergoing taxane-based chemotherapy at two main sites (University of North Carolina at Chapel Hill (UNC) Hospital, including Rex Hospital, and ...
What is the current status of trial NCT04932031?
This trial is currently terminated. The enrollment target is 123 participants. The study started on 2022-05-25. Estimated completion is 2023-11-01.
Who is sponsoring clinical trial NCT04932031?
This trial is sponsored by Sapere Bio, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.